摘要
目的分析医院获得性肺炎患者克雷伯菌、大肠埃希菌中产超广谱β-内酰胺酶菌株的发生率和耐药特点。方法选取2018年3月~2020年1月吉安市第一人民医院收治的医院获得性肺炎104例患者为研究对象进行回顾性分析。主要采用DL-96Ⅱ进行药敏试验、菌种鉴定,超广谱β-内酰胺酶菌株主要采用纸片扩散法检测,分析其发生率以及耐药特性。结果克雷伯菌与大肠埃希菌超广谱β-内酰胺酶阳性率比较,差异无统计学意义(P>0.05);大肠埃希菌超广谱β-内酰胺酶对对氨苄西林、复方新诺明、氨曲南、头孢哌酮/舒巴坦、哌拉西林/他唑巴坦、头孢他啶、左氧氟沙星、亚胺培南、头孢西丁、阿米卡星出现耐药性,且随着时间推移有提升趋势。结论医院获得性肺炎患者克雷伯菌、大肠埃希菌超广谱β-内酰胺酶菌株的发生率较高,近年耐药性也呈逐步提升趋势。
Objective To analyze the incidence and drug resistance of extended spectrumβ-lactamases in Klebsiella and Escherichia coli from patients with hospital acquired pneumonia.Methods A total of 104 patients with hospital acquired pneumonia admitted to the First People′s Hospital of Ji′an City from March 2018 to January 2020 were selected for retrospective analysis.The DL-96Ⅱwas mainly used for drug sensitivity test and strain identification,extended spectrumβ-lactamases were detected by Kirby-Bauer method,and their incidence and drug resistance characteristics were analyzed.Results There was no significant difference in the positive rate of extended spectrumβ-lactamases between Klebsiella and Escherichia coli(P>0.05).Extended spectrumβ-lactamases in Escherichia coli showed drug resistance to Ampicillin,Paediatric Compound Sulfamethoxazole Tablets,Aztreonam,Cefperazone/Sulbactam,Piperacillin/Tazobactam,Ceftazidime,Levofloxacin,Imipenem,Cefoxitin and Amikacin,and promoted over time.Conclusion The incidence of extended spectrumβ-lactamases in Klebsiella and Escherichia coli from patients with hospital acquired pneumonia is high,and drug resistance also shows gradually increasing trend in recent years.
作者
龚伟
陈樱花
赵剑敏
GONG Wei;CHEN Ying-hua;ZHAO Jian-min(Department of Laboratory,the First People′s Hospital of Ji′an City,Jiangxi Province,Ji′an 343000,China)
出处
《中国当代医药》
CAS
2021年第17期190-192,共3页
China Modern Medicine
基金
江西省吉安市科学技术局科技计划任务项目。
